Niels W.C.J. van de Donk

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Henk M. Lokhorst, Torben Plesner, Jacob P. Laubach et al. · New England Journal of Medicine · 2015 · 1.1K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Teclistamab in Relapsed or Refractory Multiple Myeloma

Philippe Moreau, Alfred L. Garfall, Niels W.C.J. van de Donk et al. · New England Journal of Medicine · 2022 · 1.1K citations · Full text

Medicine, Hematology, Immunology +17

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Philippe Moreau, Michel Attal, Cyrille Hulin et al. · The Lancet · 2019 · 953 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

Pieter Sonneveld, Hervé Avet‐Loiseau, Sagar Lonial et al. · Blood · 2016 · 929 citations · Full text

Medicine, Hematology, Oncology +15

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

Jakub Krejcik, Tineke Casneuf, Inger S. Nijhof et al. · Blood · 2016 · 918 citations · Full text

Life Sciences, Immunology, Oncology +17